NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $205.79 -3.83 (-1.83%) (As of 09/20/2024 08:54 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Charles River Laboratories International Stock (NYSE:CRL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$203.32▼$208.0350-Day Range$187.98▼$245.2952-Week Range$161.65▼$275.00Volume1.17 million shsAverage Volume591,938 shsMarket Capitalization$10.60 billionP/E Ratio24.21Dividend YieldN/APrice Target$227.55Consensus RatingHold Company OverviewCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Read More… Forget Trump and Kamala (Ad)I hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.THIS CALENDAR is the only thing that matters for you and your financial health right now. Charles River Laboratories International Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 97th PercentileCharles River Laboratories International scored higher than 97% of companies evaluated by MarketBeat, and ranked 30th out of 1,000 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.29% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 7.29% in the coming year, from $10.01 to $10.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 24.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 24.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.69.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 3.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.83% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 7.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.55 Percentage of Shares Shorted2.83% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 7.59%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.65 News SentimentCharles River Laboratories International has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Charles River Laboratories International this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. CRL Stock News HeadlinesCharles River Laboratories International (NYSE:CRL) Price Target Lowered to $190.00 at Robert W. BairdSeptember 21 at 6:59 AM | americanbankingnews.comThe Analyst Verdict: Charles River In The Eyes Of 10 ExpertsSeptember 20 at 11:29 AM | benzinga.comHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but it processes 70-80%. Now the US is coming over the top by investing $700B+ into domestic supply with the IRA and Bi-partisan Infrastructure Bill.September 23, 2024 | DealMaker (Ad)Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA ResubmissionSeptember 19, 2024 | businesswire.comOri Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and ManufacturingSeptember 18, 2024 | globenewswire.comCharles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience ResearchSeptember 17, 2024 | finance.yahoo.comCharles River Laboratories International, Inc. (NYSE:CRL) Receives $231.00 Consensus Price Target from BrokeragesSeptember 13, 2024 | americanbankingnews.comCalculating The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)September 1, 2024 | finance.yahoo.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $236.40 at the beginning of the year. Since then, CRL shares have decreased by 12.9% and is now trading at $205.79. View the best growth stocks for 2024 here. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) released its earnings results on Wednesday, August, 7th. The medical research company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.39 by $0.41. The medical research company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.03 billion. Charles River Laboratories International had a trailing twelve-month return on equity of 14.96% and a net margin of 10.83%. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's board authorized a share buyback plan on Wednesday, August 7th 2024, which permits the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board believes its stock is undervalued. Does Charles River Laboratories International have any subsidiaries? Charles River Laboratories International subsidiaries include these companies: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Top institutional shareholders of Charles River Laboratories International include Kayne Anderson Rudnick Investment Management LLC (3.71%), Clearbridge Investments LLC (2.66%), Allspring Global Investments Holdings LLC (2.43%) and Earnest Partners LLC (1.95%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Richard F Wallman. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/07/2024Today9/23/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CUSIP15986410 CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees21,800Year Founded1947Price Target and Rating Average Stock Price Target$227.55 High Stock Price Target$290.00 Low Stock Price Target$190.00 Potential Upside/Downside+10.6%Consensus RatingHold Rating Score (0-4)2.23 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$8.50 Trailing P/E Ratio24.21 Forward P/E Ratio20.56 P/E Growth3.89Net Income$474.62 million Net Margins10.83% Pretax Margin13.25% Return on Equity14.96% Return on Assets6.70% Debt Debt-to-Equity Ratio0.65 Current Ratio1.58 Quick Ratio1.21 Sales & Book Value Annual Sales$4.08 billion Price / Sales2.60 Cash Flow$17.86 per share Price / Cash Flow11.52 Book Value$70.15 per share Price / Book2.93Miscellaneous Outstanding Shares51,510,000Free Float50,840,000Market Cap$10.60 billion OptionableOptionable Beta1.36 Social Links This page (NYSE:CRL) was last updated on 9/23/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Charles River Laboratories International, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.